MDWD MediWound Ltd. IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1593984 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-16.1%
TTM net income YoY21.0%
TTM EPS YoY30.7%
Revenue 3-yr CAGR-13.8%
Net income 3-yr CAGR—
Margins
Gross margin19.2%
Operating margin-149.0%
Net margin-140.8%
FCF margin-127.5%
EBITDA margin-145.5%
Returns
ROE-63.9%
ROA-29.9%
ROIC (approx.)-65.6%
Asset turnover0.21x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.00x
Current ratio2.33x
Interest coverage-10.27x
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue32.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $16.96M | $20.22M |
| Cost of revenue | $13.71M | $17.59M |
| Gross profit | $3.25M | $2.63M |
| R&D expense | $14.32M | $8.88M |
| SG&A expense | $8.45M | $8.20M |
| Operating income | -$25.27M | -$19.40M |
| Interest expense | $2.46M | $12.81M |
| Pretax income | -$23.71M | -$30.16M |
| Income tax | $169,000 | $61,000 |
| Net income | -$23.88M | -$30.22M |
| EBITDA | -$24.68M | -$18.77M |
| EPS (basic) | -2.10 | -3.03 |
| EPS (diluted) | -2.10 | -3.03 |
| Weighted avg. shares (diluted) | 11.38M | 9.96M |
| Balance sheet | ||
| Cash & equivalents | $4.80M | $9.15M |
| Short-term investments | $48.34M | $34.01M |
| Receivables | $1.62M | $4.80M |
| Inventory | $4.09M | $2.69M |
| Current assets | $59.96M | $52.16M |
| PP&E, netmay include right-of-use assets (IFRS) | $18.64M | $14.13M |
| Intangibles | $33,000 | $99,000 |
| Total assets | $86.25M | $73.50M |
| Current liabilities | $25.71M | $26.54M |
| Total liabilities | $42.62M | $42.34M |
| Shareholders' equity | $43.63M | $31.15M |
| Shares outstanding | 12.84M | 10.79M |
| Cash flow statement | ||
| Operating cash flow | -$16.12M | -$13.62M |
| Capital expenditure | $5.50M | $6.27M |
| Free cash flow | -$21.63M | -$19.90M |
| Investing cash flow | -$17.95M | -$8.40M |
| Financing cash flow | $29.62M | $19.39M |
| Depreciation & amortization | $591,000 | $630,000 |
| Stock-based compensation | $3.11M | $3.14M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.